WEBULL
WebtradeDownload

Novavax (NVAX) Could Be 34% Overvalued Following XFG Vaccine Approvals

Simply Wall St · 20h ago

Novavax (NVAX) is back in focus after announcing that partners secured approvals for an updated Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in the U.S., EU and Japan.

The approvals have arrived as Novavax shares trade at US$9.37, with a 30-day share price return of 28.01% and a year-to-date share price return of 31.42%. However, the stock is still down over the past quarter, and the 5-year total shareholder return of 96.27% reflects a steep long term decline.

Spot 19 high quality undiscovered gems that, like Novavax, rely on partnerships and licensing to turn specialized science into potential recurring revenue streams.

After a sharp move to US$9.37 and a wide gap between that price and several fair value estimates, the question for Novavax now is where the midpoint really lies and how much of the recent news is already reflected in the price.

Most Popular Narrative: 33.9% Overvalued

At a last close of $9.37 compared with a most followed fair value of $7.00, the leading Novavax narrative frames the stock as pricing in a lot of optimism versus its discounted cash flow assumptions.

The assumed bearish price target for Novavax is $7.0, which represents up to two standard deviations below the consensus price target of $14.11. This valuation is based on what can be assumed as the expectations of Novavax's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.

Read the complete narrative. Read the complete narrative.

Want to see what is behind that lower fair value for Novavax? The narrative leans on strict revenue assumptions, steeper discounting, and a richer future earnings multiple than many investors might expect.

Result: Fair Value of $7.00 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that bearish Novavax narrative could be challenged if Matrix M licensing broadens into new indications, or if Sanofi and Pfizer partnerships deliver stronger, recurring revenue contributions.

Find out about the key risks to this Novavax narrative.

Another View On Novavax’s Valuation

The bearish narrative pegs Novavax at a fair value of $7.00 and argues the stock is overvalued. Yet our DCF model points to an estimated future cash flow value of $54.02, which implies a very different story. Which framework do you think better fits the risks you see?

For a closer look at how those cash flow assumptions are built and what would need to change for the gap to close, Look into how the SWS DCF model arrives at its fair value.

NVAX Discounted Cash Flow as at Sep 2026
NVAX Discounted Cash Flow as at Sep 2026

Next Steps

If this Novavax debate feels finely balanced, take a moment to review the data and form your own stance. Then weigh both sides through 2 key rewards and 1 important warning sign

Looking for more Novavax style investment ideas?

If the Novavax setup has you rethinking your watchlist, do not stop here. Use the Simply Wall Street Screener to uncover other focused ideas that could fit your approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.